SCHEMBL6545308

SCHEMBL6545308

N=C(N)NCCCC(N)C[O]

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TSHR P16473 1/20 0.34
HIF1A Q16665 1/20 0.34
NPY4R P50391 10/20 0.33
NPY1R P25929 7/20 0.33
NPY2R P49146 5/20 0.33
NPY5R Q15761 5/20 0.33
OTC P00480 1/20 0.31
DPP7 Q9UHL4 1/20 0.31
ALB P02768 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29404058 0.82 MEN1 (0.41) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL20822004 0.82 MEN1 (0.41) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL26614349 0.82 MEN1 (0.41) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL6545309 0.82 MEN1 (0.41) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL7158448 0.80 MEN1 (0.40) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL30158908 0.80 MEN1 (0.40) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL11535264 0.80 MEN1 (0.40) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL171399 0.80 MEN1 (0.40) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL18822222 0.80 MEN1 (0.40) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2
SCHEMBL7250717 0.79 ALOX15 (0.38) ALOX15MEN1CYP1A2KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6696500-B2 BIOACTIVE SUBSTANCE HAVING ACIDIC GROUP AND A BIODEGRADABLE POLYMER HAVING AN OPTIONALLY PROTECTED BASIC GROUP, SUCH AS A POLYLACTONE THAT HAS BEEN ESTERIFIED, AMIDATED, OR THIOESTERIFIED WITH A COMPOUND HAVING CYCLIC AMINO GROUPS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-02-24 US disclosed
EP-0815853-B1 Sustained-release preparation for bioactive substance having an acidic group TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2004-01-21 EP disclosed
US-20010038854-A1 Sustained-release preparation TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2001-11-08 US disclosed
US-6264970-B1 BIODEGRADABLE POLYMER TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-07-24 US disclosed
EP-0815853-A2 Sustained-release preparation for bioactive substance having an acidic group TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010038854-A1 Sustained-release preparation BMP2, PGF, AREG ALOX15 1152/4885MEN1 3623/4885CYP1A2 4062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.